Hepatitis A Virus Panel

Also known as: HEP A PAN

Clinical Use

Use

The Hepatitis A Virus Panel is a diagnostic test used to detect the presence of hepatitis A antibodies in the blood. It includes Hepatitis A Antibodies, Total and Hepatitis A Antibody, IgM, both of which help determine the immune status or recent infection of a patient with HAV. The test can aid in diagnosing acute HAV infection or assessing immunity following vaccination. It is typically ordered for individuals presenting with symptoms consistent with hepatitis infection.

Special Instructions

Not provided.

Limitations

The panel may not fully differentiate between recent infection and the immune response following vaccination against Hepatitis A. False positives can occur. Borderline results on IgM may require retesting at one-week intervals to determine seroconversion status. Unacceptable conditions include specimens with particulate matter, severely hemolyzed, lipemic, or heat-inactivated specimens, and those collected in citrate-based anticoagulant.

Test Details

New York Approved

Methodology

Immunoassay (CLIA)

Biomarkers

Hepatitis A Antibodies, Total

Protein

Negative

Other • Binary (Detected / Not Detected)

Hepatitis A Antibody, IgM

Protein

Negative

Other • Binary (Detected / Not Detected)

LOINC Codes

Order Codes

13950-1 - HAV IgM SerPl Ql IA
13951-9 - HAV Ab Ser Ql IA
53776-1 - HAV Ab Ser-Imp

Result Turnaround Time

1 day

Specimen

Serum

Volume

1 mL

Minimum Volume

0.5 mL

Container

Serum separator tube

Collection Instructions

Collect specimen in a serum separator tube. Also acceptable: Lavender (EDTA) or pink (K2EDTA). Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer to an ARUP standard transport tube.

Patient Preparation

Refer to individual components.

Storage Instructions

Refrigerated.

Causes for Rejection

Specimens containing particulate material. Severely hemolyzed or lipemic specimens. Heat-inactivated specimens. Specimens collected in citrate-based anticoagulant.